{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["tagraxofusp"]],"indication":"blastic plasmacytoid dendritic cell neoplasm or AML","name":"NCT02113982","nct_id":"NCT02113982","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02113982. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Intervention: Tagraxofusp","label":"First-Line Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","type":"EXPERIMENTAL"},{"description":"Intervention: Tagraxofusp","label":"Relapse/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","type":"EXPERIMENTAL"},{"description":"Intervention: Tagraxofusp","label":"Acute Myeloid Leukemia","type":"EXPERIMENTAL"}],"collaborators":["The Leukemia and Lymphoma Society"],"completion_date":{"date":"2020-03-12","type":"ACTUAL"},"conditions":["Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","Acute Myeloid Leukemia (AML)"],"enrollment":{"count":138,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Tagraxofusp","otherNames":["SL-401"],"type":"DRUG"}],"last_update":"2024-08-01","lead_sponsor":"Stemline Therapeutics, Inc.","official_title":"Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2020-02-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"MTD (Stage 1)","timeFrame":"21-day period after the first dose (cycle 1)"},{"measure":"CR Rate in First-line BPDCN (Stage 3, Pivotal Cohort)","timeFrame":"at pre-defined treatment cycle intervals from randomization up to disease progression, up to 3.5 years"}],"references":[{"citation":"Konopleva M, Pemmaraju N, Sweet KL, Stein AS, Rizzieri DA, Wang ES, Vasu S, Rosenblat T, Zuurman M, Gupta I, Lane AA. Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm. Cancer. 2026 Jan 1;132(1):e70243. doi: 10.1002/cncr.70243.","pmid":"41486505","type":"DERIVED"},{"citation":"Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 Sep 10;40(26):3032-3036. doi: 10.1200/JCO.22.00034. Epub 2022 Jul 12.","pmid":"35820082","type":"DERIVED"},{"citation":"Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105.","pmid":"31018069","type":"DERIVED"}],"start_date":{"date":"2014-09"},"study_type":"INTERVENTIONAL","title":"Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia","url":"https://clinicaltrials.gov/study/NCT02113982"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02113982"}